Century Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Century Therapeutics disminuyan en un 7.6% al año. Se prevé que el BPA aumente en un 16.5% al año.

Información clave

-7.6%

Tasa de crecimiento de los beneficios

16.51%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	25.2%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	19 May 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Artículo de análisis • Dec 17

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. ( NASDAQ:IPSC ) shareholders have had their patience rewarded with a 32% share price jump in...

Artículo de análisis • Nov 30

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Artículo de análisis • Oct 08

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Century Therapeutics, Inc.'s ( NASDAQ:IPSC ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong...

Seeking Alpha • Jun 20

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Summary Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses. Read the full article on Seeking Alpha

Artículo de análisis • Mar 06

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Feb 01

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Summary Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions. Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a complete clinical response. However, Century Therapeutics has a limited cash position and needs to prove the efficacy of their therapies before being considered a confident investment. Read the full article on Seeking Alpha

Artículo de análisis • Oct 23

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Aug 25

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Century Therapeutics (NASDAQ:IPSC) will begin a phase 1 study of its allogeneic cell therapy CNTY-101 by the end of the year after receiving Investigational New Drug clearance from the US FDA. CNTY-101 is under investigation for relapsed or refractory CD19 positive B-cell malignancies. In the ELiPSE-1 study, all patients will receive an initial standard dose of conditioning chemotherapy. Schedule A consists of a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101. CNTY-101 is derived from a clonal induced pluripotent stem cell (iPSC) master cell bank that yields homogeneous product. Seeking Alpha's Quant Rating views Century (IPSC) as a hold with strong grades for profitability and momentum.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:IPSC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2028	N/A	-120	-158	N/A	2
12/31/2027	N/A	-107	-145	N/A	4
12/31/2026	N/A	-93	-138	N/A	4
3/31/2026	N/A	-108	-95	-95	N/A
12/31/2025	109	-10	-105	-104	N/A
9/30/2025	113	-26	-113	-112	N/A
6/30/2025	114	-23	-115	-115	N/A
3/31/2025	115	-22	-115	-115	N/A
12/31/2024	7	-127	-110	-110	N/A
9/30/2024	3	-130	-113	-112	N/A
6/30/2024	2	-131	-103	-97	N/A
3/31/2024	1	-133	-99	-89	N/A
12/31/2023	2	-137	-102	-88	N/A
9/30/2023	2	-129	-104	-85	N/A
6/30/2023	5	-127	-121	-96	N/A
3/31/2023	6	-125	-133	-102	N/A
12/31/2022	5	-131	-17	14	N/A
9/30/2022	5	-127	-28	13	N/A
6/30/2022	2	-123	-34	13	N/A
3/31/2022	1	-115	-27	20	N/A
12/31/2021	N/A	-96	-134	-89	N/A
9/30/2021	N/A	-83	-108	-78	N/A
6/30/2021	N/A	-70	-82	-63	N/A
3/31/2021	N/A	-62	-66	-57	N/A
12/31/2020	N/A	-54	-51	-41	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que IPSC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que IPSC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que IPSC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de IPSC crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que IPSC no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de IPSC se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/05/25 16:27
Precio de las acciones al final del día	2026/05/22 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Century Therapeutics, Inc. está cubierta por 9 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Geoffrey Meacham	BofA Global Research
Chen Yang	BofA Global Research
William Maughan	Canaccord Genuity

Century Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 22% to US$3.67

Price target decreased by 11% to US$4.25

Consensus revenue estimates increase by 115%

Price target decreased by 8.3% to US$4.40

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 2,092%

Recent updates

New major risk - Financial position

Price target increased by 22% to US$3.67

Century Therapeutics, Inc., Annual General Meeting, Jun 11, 2026

Full year 2025 earnings: EPS exceeds analyst expectations

Century Therapeutics, Inc. announced that it has received $134.997458 million in funding from a group of investors

New major risk - Shareholder dilution

Century Therapeutics, Inc. Announces Resignation of Carlo Rizzuto as Director., Effective December 18, 2025

New minor risk - Share price stability

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. Announces Board and Committee Appointments

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.37 loss in 3Q 2024)

Century Therapeutics, Inc. Announces New Beta Islet Program for Type 1 Diabetes

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Price target decreased by 11% to US$4.25

Nasdaq Grants Century Therapeutics an Additional 180 Calendar Day Period, or Until February 23, 2026, to Regain Compliance with the Bid Price Rule

Century Therapeutics, Inc. Announces Board and Committee Changes, Effective August 14, 2025

Century Therapeutics, Inc. Announces Departure of Morgan Conn, Ph.D. as the Chief Financial Officer, Effective July 11, 2025

Consensus revenue estimates increase by 115%

Price target decreased by 8.3% to US$4.40

New major risk - Financial position

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 2,092%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Century Therapeutics, Inc. Provides Business Update for Clinical Pipeline for CNTY-101

Century Therapeutics Receives A Notification Letter from the Nasdaq Stock Market Regarding Listing Rule 5450(a)(1)

Price target increased by 8.0% to US$9.00

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-Derived iNK Cell Therapy Cnty-101 in B-Cell Mediated Autoimmune Diseases

New major risk - Shareholder dilution

New minor risk - Market cap size

Consensus revenue estimates increase by 23%

Price target decreased by 11% to US$10.40

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Century Therapeutics, Inc. Appoints Chad Cowan as Chief Scientific Officer, Effective October 1, 2024

Century Therapeutics, Inc. Appoints Morgan Conn as Chief Financial Officer, Effective October 14, 2024

Price target decreased by 7.1% to US$11.33

Consensus revenue estimates increase by 24%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting

Price target decreased by 18% to US$12.20

Consensus revenue estimates increase by 77%

Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.53 loss in 1Q 2023)

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations